Pathophysiology of parathyroid hyperplasia in chronic kidney disease: Preclinical and clinical basis for parathyroid intervention

NDT Plus

Volumn 1, Issue SUPPL.3, 2008, Pages

  Goto, Shunsuke ^a   Komaba, Hirotaka ^a   Fukagawa, Masafumi ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic kidney disease; Fibroblast growth factor 23; Parathyroid hyperplasia; Parathyroid intervention; Secondary hyperparathyroidism

Indexed keywords

22 OXACALCITRIOL; ALCOHOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM SENSING RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; TRANSFORMING GROWTH FACTOR ALPHA; VITAMIN D RECEPTOR;

AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MECHANISM; GENE EXPRESSION; HEMODIALYSIS PATIENT; HUMAN; NODULAR HYPERPLASIA; NONHUMAN; ONCOGENIC OSTEOMALACIA; PARATHYROID FUNCTION; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PATHOGENESIS; PATHOPHYSIOLOGY; PERCUTANEOUS ETHANOL INJECTION THERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; REMISSION; REVIEW; SECONDARY HYPERPARATHYROIDISM; THERAPY; X LINKED HYPOPHOSPHATEMIC RICKETS;

EID: 48749131218     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn079     Document Type: Review

References (84)

1. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000; 11: 1141-1152
2. Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int 2006; 70(Suppl 102): S3-S7
3. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
4. Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007; 18: 875-885
5. Fukagawa M, Kazama JJ, Shigematsu T. Management of the patients with advanced secondary hyperparathyroidism: the Japanese approach. Nephrol Dial Transplant 2002; 17: 1553-1557
6. Fukagawa M, Kitaoka M, Tominaga Y et al. Guideline for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant 2003; 18(Suppl 3): iii31-iii33
7. Tominaga Y, Tanaka Y, Sato K et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13: 78-86
8. Albright F, Drake TG, Sulkowitch HW. Renal osteitis fibrosa cystica. Report of a case with discussion of metabolic aspects. Johns Hopkins Med J 1937; 60: 377-385
9. Berson SA, Yalow RS. Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab 1968; 28: 1037-1047
10. Reiss E, Canterbury JM, Kanter A. Circulating parathyroid hormone concentration in chronic renal insufficiency. Arch Intern Med 1969; 124: 417-422
11. Slatopolsky E, Caglar S, Pennell JP et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971; 50: 492-499
12. Bricker NS. On the pathogenesis of the uremic state. An exposition of the 'trade-off hypothesis'. N Engl J Med 1972; 286: 1093-1099
13. Laflamme GH, Jowsey J. Bone and soft tissue changes with oral phosphate supplements. J Clin Invest 1972; 51: 2834-2840
14. Rutherford WE, Bordier P, Marie P et al. Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J Clin Invest 1977; 60: 332-341
15. Portale AA, Booth BE, Halloran BP et al. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984: 73: 1580-1589
16. Wilson L, Felsenfeld A, Drezner MK et al. Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D. Kidney Int 1985; 27: 565-573
17. Lopez-Hilker S, Galceran T, Chan YL et al. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 1986; 78: 1097-1102
18. Cantley LK, Russell J, Lettieri D et al. 1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology 1985; 117: 2114-2119
19. Silver J, Naveh-Many T, Mayer H et al. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986; 78: 1296-1301
20. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
21. Andress DL, Norris KC, Coburn JW et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-279
22. Martin KJ, Gonzalez EA, Gellens M et al. 19-Nor-1-alpha-25- dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432
23. Tan AU Jr, Levine BS, Mazess RB et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51: 317-323
24. Portale AA, Halloran BP, Murphy MM et al. Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in human. J Clin Invest 1986; 77: 7-12
25. Yi H, Fukagawa M, Yamato H et al. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure rats: possible direct role of phosphorus. Nephron 1995; 70: 242-248
26. Combe C, Aparicio M. Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 1994; 46: 970-976
27. Slatopolsky E, Finch J, Denda M et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534-2540
28. Almaden Y, Canalejo A, Hernandez A et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996; 11: 970-976
29. Tatsumi S, Segawa H, Morita K et al. Molecular cloning and hormonal regulation of PiT-1, a sodium-dependent phosphate cotransporter from rat parathyroid glands. Endocrinology 1998; 139: 1692-1699
30. Yalcindag C, Silver J, Naveh-Many T. Mechanism of increased parathyroid hormone mRNA in experimental uremia: roles of protein RNA binding and RNA degradation. J Am Soc Nephrol 1999; 10: 2562-2568
31. Sela-Brown A, Silver J, Brewer G et al. Identification of AUF1 as a parathyroid hormone mRNA 3′ untranslated region-binding protein that determines parathyroid hormone mRNA stability. J Biol Chem 2000; 275: 7424-7429
32. Almaden Y, Canalejo A, Ballesteros E et al. Effect of high extracellular phosphate concentration on arachidonic acid production by parathyroid tissue in vitro. J Am Soc Nephrol 2000; 11: 1712-1718
33. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995; 11: 130-136
34. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutation in FGF23. Nat Genet 2000; 26: 345-348
35. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505
36. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519-1524
37. Nishi H, Nii-Kono T, Nakanishi S et al. Intravenous calcitriol therapy increases serum concentration of fibroblast growth factor 23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005; 101: c94-c99
38. Saito H, Meda A, Ohtomo S et al. Circulating FGF-23 is regulated by 1 alpha, 25-dihydroxyvitamine D3 and phosphate in vivo. J Biol Chem 2005; 280: 2543-2549
39. Collins MT, Lindsay JR, Jain A et al. Fibroblast growth factor-23 is regulated by 1 alpha, 25-dihydroxyvitamin D. J Bone Miner Res 2005; 20: 1944-1950
40. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 291: E38-E49
41. Masuyama R, Stockmans I, Torrekens S et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 2006; 116: 3150-3159
42. Perwad F, Zhang MY, Tenenhouse HS et al. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293: F1577-F1583
43. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279
44. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor-23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256
45. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215
46. Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrol Dial Transplant 2005; 20: 1295-1298
47. Wang Q, Palnitkar S, Parfitt AM. The basal rate of cell proliferation in normal human parathyroid tissue: implications for the pathogenesis of hyperparathyroidism. Clin Endocrinol 1997; 46: 343-349
48. Naveh-Many T, Rahaminov R, Livni N et al. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995; 96: 1786-1793
49. Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe formof parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1443
50. Tokumoto M, Tsuruya K, Fukuda K et al. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 2002; 62: 1196-1207
51. Kifor O, Moore FD Jr, Wang P et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 1598-1606
52. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51: 328-336
53. Dusso AS, Pavlopoulos T, Naumovich L et al. p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 2001; 59: 855-865
54. Dusso AS, Sato T, Arcidiacono MV et al. Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int 2006; 70(Suppl 102): S8-S11
55. Arcidiacono MV, Sato T, Alvarez-Hernandez D et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol 2008; 19: 310-320
56. Arnold A, Brown MF, Urena P et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95: 2047-2053
57. Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67: 1171-1178
58. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005; 67: 1120-1125
59. Sato T, Tominaga Y, Ueki T et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004; 44: 481-487
60. Urena-Torres P, Friedlander G, de Vernejoul MC et al. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 2008; 73: 102-107
61. Chikazu D, Hakeda Y, Ogata N et al. Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase. J Biol Chem 2000; 275: 31444-31450
62. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281: 6120-6123
63. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774
64. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008
65. Fukagawa M, Okazaki R, Takano K et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 1990; 323: 421-422
66. Tanaka M, Tominaga Y, Sawatari E et al. Infarction of mediastinal parathyroid gland causing spontaneous remission of secondary hyperparathyroidism. Am J Kidney Dis 2004; 44: 762-767
67. Komaba H, Takeda Y, Abe T et al. Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient. Nephrol Dial Transplant 2008; 23: 1760-1762
68. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patient. Nephron 1994; 68: 221-228
69. Okuno S, Ishimura E, Kitatani K et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003; 18: 2613-2621
70. Tominaga Y, Inaguma D, Matsuoka S et al. Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial 2006; 10: 198-204
71. Tominaga Y, Uchida K, Haba T et al. More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis 2001; 38(Suppl l): S166-S171
72. Koiwa F, Kakuta T, Tanaka R et al. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2007; 22: 522-528
73. Kitaoka M, Fukagawa M, Fukuda N et al. Direct injections of calciriol into parathyroid hyperplasia in chronic dialysis patients with severe parathyroid hyperfunction. Nephrology 1995; 1: 563-568
74. Kitaoka M, Onoda NM, Kitamura H et al. Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicenter trial. Nephrol Dial Transplant 2003; 18(Suppl 3): iii38-iii41
75. Shiizaki K, Hatamura I, Negi S et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 2003; 64: 992-1003
76. Shiizaki K, Negi S, Hatamura I et al. Biochemical and cellular effect of direct maxacalcitol injection into parathyroid gland in uremic rat. J Am Soc Nephrol 2005; 16: 97-108
77. 2+ for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics. J Pharmacol Sci 2005; 97: 355-360
78. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
79. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807
80. Fukagawa M, Yumita S, Akizawa T et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008; 23: 328-335
81. Srinivas TR, Schold JD, Womer KL et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 323-326
82. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007; 22: 577-583
83. Kruse AE, Eisenberger U, Frey FJ et al. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2007; 22: 2362-2365
84. Taniguchi M, Tokumoto M, Matuo D et al. Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int 2006; 70: 363-370